Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Innovation Stock C fund, which has shown a recent decline in net value but strong performance over the past six months and year-to-date [1] - The latest net value of the fund is 1.3561 yuan, reflecting a decrease of 0.74% [1] - The fund's one-month return is -1.63%, ranking 606 out of 673 in its category, while its six-month return is 43.34%, ranking 18 out of 659, and year-to-date return is 36.66%, ranking 22 out of 659 [1] Group 2 - The top ten stock holdings of the China Europe Medical Innovation Stock C fund account for a total of 75.62%, with significant positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and others [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field, having worked with various funds since joining China Europe Fund Management in 2014 [2]

康龙化成（300759）公告，信息披露义务人信中康成及其一致行动人信中龙成合计减持公司股份5521.3 万股，占公司总股本的3.36%。此次减持包括集中竞价交易和大宗交易两种方式，减持期间为2023年1 月10日至2025年7月9日。此次减持是由于信息披露义务人自身资金需求以及公司历次激励计划归属的限 制性股票上市、回购注销股份、权益分派等原因导致股份比例被动变动。未来12个月内，信息披露义务 人将继续减持股份并计划在未来12个月内无增持计划。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-037 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东权益变动 触及 1%和 5%整数倍的提示性公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持进展告知函》，获悉信中康成和信中龙成因减持、 公司总股本变动等原因导致权益变动触及 1%和 5%的整数倍。现将有关情况公 告如下： 1.基本情况 信息披露义务人 （一） 深圳市信中康成投资合伙企业（有限合伙） 住所 深圳市前海深港合作区南山街道兴海大道 3046 号香江金 融大厦 1314-B8 信息披露义务人 （二） 深圳市信 ...

康龙化成（北京）新药技术股份有限公司 简式权益变动报告书 上市公司名称：康龙化成（北京）新药技术股份有限公司 股票上市地点：深圳证券交易所（A股）、香港联合交易所（H股） 股票简称：康龙化成（A股、H股） 股票代码：300759.SZ/03759.HK 信息披露义务人（一）：深圳市信中康成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区南山街道兴海大道3046号香江金融大厦1314-B8 通讯地址：北京市朝阳区京城大厦16层 信息披露义务人（二）：深圳市信中龙成投资合伙企业（有限合伙） 住所：深圳市前海深港合作区前湾一路1号A栋201室（入驻深圳市前海商务秘 书有限公司） 通讯地址：北京市朝阳区京城大厦16层 签署日期：2025年7月9日 2 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 （以下简称"《准则15号》"）及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据 ...

市场的复苏从来不是线性上升的过程，但产业LP的重新进场，进一步带动市场信心的回 归。 近两年，曾经叱咤风云的互联网巨头们，在LP版图上几近隐退。 而就在近期，战局突变：腾讯重金押注"并购女王"刘晓丹的晨壹基金，阿里悄然落子清华系早期阵地， 京东以5亿元重仓GP…… 悄然间，互联网三巨头正集体回归LP战场。 三巨头齐回归 过去两年，曾活跃于LP领域的互联网巨头们纷纷离场，GP背后鲜少出现互联网巨头的身影，而就在这 几天，久违的一幕重现了。 起因是7月3日的一则工商变更信息，将腾讯再度拉回到创投行业的视野中。 据企查查APP显示：7月3日，上海晨峦企业管理合伙企业（有限合伙）发生工商变更，新增合伙人名单 中赫然出现了广西腾讯创业投资有限公司的身影。一同进入的还有深圳舟益管理咨询合伙企业——同为 腾讯系子公司。 腾讯此次对晨壹基金的出资总额超过2亿元。 由"并购女王"刘晓丹执掌的基金，去年刚迎来阿里系悍将张勇、胡晓加盟，如今腾讯入场，被视为是其 对当下最火热的并购赛道的战略卡位。 据FOFWEEKLY观察，这已是腾讯2025年内第三次以LP身份出手了： 今年2月份，深圳市腾讯产业投资基金有限公司出资1亿，参投苏州杏 ...

Core Viewpoint - The return of major internet giants as Limited Partners (LPs) signals a resurgence of market confidence and a potential turning point for the venture capital industry in 2025 [2][3][21]. Group 1: Return of Internet Giants - After a two-year hiatus, Tencent, Alibaba, and JD.com are re-entering the LP landscape, indicating a shift in market dynamics [3][12]. - Tencent has made significant investments, including over 200 million yuan in the Morning One Fund, led by renowned investor Liu Xiaodan [8][9]. - JD.com has also made a notable return, investing 500 million yuan in a new fund, further emphasizing the trend of major players re-engaging in the market [11]. Group 2: Market Recovery Indicators - The venture capital market has faced challenges, but signs of recovery are emerging, with increased investor activity and shorter decision-making cycles [15][17]. - The recent establishment of new funds, such as the 700 million yuan fund by Chaoxi Capital, shows a growing interest from industry LPs, with 60% of contributions coming from them [16]. - The combination of policy easing and technological breakthroughs is reshaping the value logic of the venture capital market, leading to renewed confidence among investors [17][18]. Group 3: Strategic Focus of LPs - Industry LPs are increasingly focusing on "industry synergy and ecological control," with a preference for GPs that demonstrate high-quality investment projects [18]. - Recent investments from various LPs, including Ningde Times and Kanglong Chemical, are concentrated in future industries like robotics and AI, reflecting a strategic shift in investment focus [18]. Group 4: Future Outlook - The year 2025 is anticipated to be a new starting point for the venture capital industry, with a positive outlook on the development of future industries [19][21]. - The collective return of major LPs and the increased activity of state-owned LPs are clear indicators of a warming market, despite ongoing challenges [21].

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line including drugs and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 796 million yuan, a year-on-year decrease of 16.49% [1] - The net profit for the same period was 25.65 million yuan, reflecting a year-on-year decline of 9.35% [1] - The sales gross margin stood at 27.96% [1] Market Position - The company's stock closed at 2.19 yuan, with a rise of 1.86%, resulting in a rolling price-to-earnings (PE) ratio of 66.17 times [1] - The total market capitalization of the company is 7.418 billion yuan [1] - In comparison to the medical services industry, which has an average PE of 43.60 times and a median of 46.78 times, New Mile ranks 34th in terms of PE ratio [2] Shareholding Structure - As of the first quarter of 2025, seven institutions hold shares in New Mile, including five other entities, one brokerage, and one fund, with a total holding of 1.3909269 billion shares valued at 3.436 billion yuan [1]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Market Overview - The Hang Seng Index rose by 260 points or 1.1%, closing at 24,148 points, driven by a rebound in technology stocks[1] - The Hang Seng Tech Index increased by 1.8%, closing at 5,325 points, with a total market turnover exceeding HKD 213.3 billion[1] - Net inflow into Hong Kong Stock Connect was HKD 386 million, indicating positive sentiment in the market[1] Sector Performance - Cathay Financial International (1788 HK) surged by 28.5%, becoming the most actively traded stock with a turnover of HKD 12.8 billion[1] - Other notable performers included Kuaishou (1024 HK), which rose by 5.2%, reaching a three-month high[1] - The gaming, cultural tourism, brokerage, and consumer electronics sectors showed strong performance, with major tech stocks like Alibaba (9988 HK) and Meituan (3690 HK) rising by 1.5% and 3.6% respectively[1] Economic Indicators - The new housing transaction volume in 30 major cities reached 1.89 million square meters, a year-on-year decline of 1.1%, showing improvement compared to the previous week's 23.1% drop[5] - The inventory-to-sales ratio for major cities was 63.1, higher than last year's 59.7 but lower than the previous week's 68.2[7] - Land transaction volume in 100 major cities increased by 15.3% year-on-year, totaling 2.063 million square meters[8] Policy and Market Outlook - The market is expected to maintain high-level fluctuations, with a focus on technology stocks for further upward movement[2] - Long-term capital is improving, suggesting no need for significant reduction in positions[2] - The government is expected to implement supportive policies to stabilize the real estate market, which may benefit both state-owned and local enterprises[11]

Group 1 - The core point of the article highlights the performance and holdings of the GF Healthcare Stock A fund, which has a recent net value of 1.8687 yuan and a one-month return of -2.29% [1] - The fund's six-month return stands at 19.73%, ranking 84 out of 417 similar funds, while its year-to-date return is 15.61%, ranking 83 out of 417 [1] - The top ten holdings of the fund account for a total of 48.15%, with notable positions in companies such as Zai Lab (10.52%), Kelun Pharmaceutical (8.39%), and Hengrui Medicine (5.17%) [1] Group 2 - The GF Healthcare Stock A fund was established on August 10, 2017, and as of March 31, 2025, it has a total scale of 5.237 billion yuan [1] - The fund manager, Wu Xingwu, has extensive experience in the investment management field, having held various positions in different funds since 2015 [2]